CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023

21 июн 2023 07:59:39 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 июн 2023 07:30:09 Источник Nasdaq GlobeNewswire

Crinetics to Highlight Broad Pipeline at ENDO 2023

09 июн 2023 07:30:08 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 май 2023 16:21:55 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

04 май 2023 16:05:12 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 апр 2023 16:31:01 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 мар 2023 16:37:50 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

28 фев 2023 16:05:39 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 фев 2023 17:21:42 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

10 фев 2023 08:01:33 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 янв 2023 16:48:48 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference

09 янв 2023 08:01:39 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 дек 2022 16:01:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Provides Update on CRN04777 Program

28 ноя 2022 08:00:01 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

22 ноя 2022 08:00:02 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

14 ноя 2022 08:00:02 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 ноя 2022 16:30:43 Источник Nasdaq GlobeNewswire

Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

13 окт 2022 08:00:02 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 окт 2022 16:57:25 Источник Nasdaq GlobeNewswire

Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism

06 окт 2022 08:00:02 Источник Nasdaq GlobeNewswire